Cogitum

Formulation and packaging

Active ingredient: N-Acetylaspartic acid 250 mg

Inactive ingredients: Fructose ÔÇô 1,000 mg, methylparaben ÔÇô 15 mg, banana flavoring ÔÇô 7 mg, purified water ÔÇô up to 10 ml

30 ampules per pack, 10 ml

Application and dosage

Oral administration. The dosage is to be determined by the doctor.

The average dose for adults is 3 ampules per day: 2 in the morning and 1 before sleep.

Dosage for children aged 7 to 10 is 1 ampule in the morning. Dosage for children aged 10 to 18 is 2 ampules in the morning.

Side effects

Allergic response.

Storage conditions

Keep out of the reach of children. Store in a dark place at a temperature not higher than 25┬░C. Shelf life ÔÇô 3 years.

Cogitum is an adaptogen with tonic and stimulating properties. It has a 40-year-long track record of successful application.

Cogitum is widely used in pediatrics and child neurology for treating delayed development, asthenic syndrome and for increasing endurance and mental performance in children and adolescents during high loads. The drug is prescribed in children aged 7 years and older. It enhances memory due to D-Aspartic acid which is a well-known metabolite.

Cogitum is well tolerated in children and has a significant effect. However it does not provide for an immediate effect as the childÔÇÖs mental state improves gradually.

Cogitum is also a good option for adults in case of asthenia, heavy workload, recovery from different diseases or the need for increasing mental performance.

Pharmacodynamic properties

The drug is based on N-Acetylaspartic acid, which is a biologically active compound contained in the central nervous system (CNS). The drug stabilizes the nervous regulation and has a stimulating effect.

Indications:

  • as part of complex therapy of asthenic syndrome;
  • fatigue with/without low mood;
  • as an adjuvant for antidepressants;
  • in pediatrics Cogitum can be used as part of complex therapy of: intellectual disability, birth defects of the central nervous system, delayed mental and speech development, delay in motor skills development, etc.

Contradictions:

    • Hypersensitivity to N-Acetylaspartic acid or any other component of the drug
      Children under 7 years of age (no clinical data)
      Pregnancy (lack of clinical data)
    1. A Soulairac (1966) Examination of posture regulation by statokinesimetry. Its application to the study of vigilance levels in the normal subject before and after treatment with PC 63-14 https://www.ncbi.nlm.nih.gov/pubmed/4384261
    2. M Lambert (1967) Alcoholic disintoxication therapy and psychiatry. The place of PC 63-14 (cogitum) https://www.ncbi.nlm.nih.gov/pubmed/5613040
    3. J Guyotat (1968) Clinical trial in hospital setting of PC-63 14 (Cogitum). 30 cases https://www.ncbi.nlm.nih.gov/pubmed/4391394
    4. A Soulairac, N Aymard (1968) Neuropsychic disorders due to alcoholism: clinical and biologic results of their treatment by PC 63-14 (dipotassium acetyl-amino-succinate) https://www.ncbi.nlm.nih.gov/pubmed/4392390
    5. M Portmann, G Lacher (1968) Various reflections apropos of the use of PC 63-14 in reception deafness https://www.ncbi.nlm.nih.gov/pubmed/4388110
    6. P Orsini (1969) Acoustic trauma. Therapeutic trial of PC 63-14 (cogitum) https://www.ncbi.nlm.nih.gov/pubmed/4388850
    7. C Bouvier, A Masquin (1969) Therapeutic effects of PC 63-14 in psychiatric practice https://www.ncbi.nlm.nih.gov/pubmed/5363736
    8. Dubovtseva et al (1999) New approaches in the treatment of speech disorders in children with an organic brain lesion https://www.ncbi.nlm.nih.gov/pubmed/4388850
    9. O Milovanova, S Astanina (2016) Treatment of asthenoneurotic disorders in children https://www.ncbi.nlm.nih.gov/pubmed/28139636


    Type: Unknown Type




    CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT